Eli Lilly and Novo Nordisk, pharmaceutical companies specializing in diabetes medications, experienced a decline in their stock values following a statement by President Donald Trump. In a public address, Mr. Trump expressed his desire for a price of $150 for the GLP-1 drug, a breakthrough treatment for type 2 diabetes. The announcement has generated market reaction as investors evaluate the potential impact on the companies’ financial outlook and future growth prospects. The market’s response is currently being monitored, with analysts offering varying perspectives on the significance of the statement.
Credits: US Top News and Analysis
